15 Oct EraGen appoints Inter Medico as Canadian distributor
Madison, Wis. – EraGen Biosciences, Inc. today announced it has appointed Inter Medico, the largest privately-owned medical diagnostics distributor in Canada, as the exclusive distributor of the company’s molecular diagnostic products in the Canadian market.
Inter Medico has a long and successful history of serving Canada’s foremost clinical laboratories and hospitals. The distributor’s experienced, market-leading sales team is supported by highly-trained technical support specialists. Inter Medico aggressively markets the products it distributes through a team of professionals with a broad range of expertise specific to the Canadian molecular diagnostics market.
Inter Medico will distribute several EraGen molecular tests that recently received Health Canada approval for marketing as in vitro diagnostics. The approved tests are performed on the company’s easy-to-use MultiCode RTx real-time PCR system. The system simplifies and enhances traditional real-time PCR, providing workflow, time-to-result, and flexibility benefits to clinicians and laboratories.
“EraGen’s entry into the Canadian market commences our planned expansion into lucrative, rapidly-growing molecular diagnostics markets outside of the United States,” said Irene Hrusovsky, M.D., president and chief executive of EraGen. “As we begin that expansion, we are pleased to partner with Canada’s leading medical diagnostics distributor. Inter Medico has a strong track record of introducing innovative technologies to the Canadian diagnostics market and we look forward to a successful, productive partnership. We expect to seek Health Canada approval for additional EraGen tests and will bring them to market through Inter Medico upon approval.”
“Inter Medico is delighted to be adding EraGen’s menu of recently-approved molecular diagnostic products to our portfolio,” said Dan Lichtman, president and chief executive of Inter Medico. “We share EraGen’s commitment to innovative molecular diagnostic tests and are very pleased to be bringing the performance, flexibility and ease of use of its MultiCode® chemistry to hospitals and laboratories across Canada.”
About EraGen Biosciences
EraGen Biosciences Inc. develops, manufactures and markets molecular reagent products that are driving a new era in clinical diagnostics. The company’s in-market and pipeline products, based on its novel, patented MultiCode® platform chemistry, are the next generation of DNA- and RNA-based testing for the early detection of infectious diseases and genetic-based conditions. EraGen’s expanding menu of high quality, easy-to-use products position the company for leadership in the molecular diagnostics market.